Abstract: The present invention relates to compounds of Formulas I-IV, which are salts of special lipid mediators of inflammation, compositions containing same, and methods of using same in the treatment of various diseases and disorders characterized by chronic or excessive inflammation, or both.

Abstract: The disclosure discloses a fatty acid synthase inhibitor and application thereof and belongs to the technical field of medical biology. The fatty acid synthase inhibitor of the disclosure can significantly inhibit the activity of fatty acid synthase without affecting normal expression, and adjust the ratio of fatty acids in cells. The fatty acid synthase inhibitor of the disclosure has a good tumor proliferation inhibitory effect, can arrest the growth cycle of tumor cells in the interphase, prevent tumor cell division, inhibit tumor cell proliferation, promote tumor cell apoptosis and exert a tumor treatment effect, can be used to treat tumors and metabolism related diseases, and has an important clinical application prospect.

Abstract: Methods of identification of inhibitors of calcium release-activated calcium (CRAC) channel and small molecule inhibitors of CRAC channel, including methods of their synthesis and pharmaceutical use, are disclosed.

Abstract: This disclosure provides compounds, pharmaceutical compositions, and methods of use for the prevention and treatment of inflammatory diseases or degenerative diseases including neurodegenerative diseases. Embodiments of the present disclosure provide compounds related to very long chain polyunsaturated fatty acids, pharmaceutical compositions containing the provided compounds, and methods of treating a subject with a condition or disease using provided compounds or pharmaceutical compositions.

Abstract: Provided is a method of reducing autoimmunity, including reducing an amount of self-reactive B cells in a subject expressing elevated levels of an autoantibody, wherein reducing includes administering 2-hydroxyoleic acid to the subject. Also provided is a method of treatment including administering 2-hydroxyoleic acid to a subject expressing elevated levels of an auto-antibody. Also provided is a method of promoting B cell tolerance, including promoting apoptosis of self-reactive B cells in a subject, wherein promoting includes administering 2-hydroxyoleic acid to the subject.

Abstract: Provided are: a composition containing 96-99 area % of eicosapentaenoic acid alkyl ester, the composition having an arachidonic acid alkyl ester content of 0.7 area % or less, and an eicosapentaenoic-acid-alkyl-ester mono-trans isomer content of 2.5 area % or less; and a method for producing a composition containing a high concentration of eicosapentaenoic acid alkyl ester, the method including performing precision distillation on a composition containing eicosapentaenoic acid alkyl ester, obtained by alkyl esterification of a raw material oil containing eicosapentaenoic acid, under a vacuum of 0.2 Torr or lower and a temperature of 190° C. or lower in the entire column, and performing a concentration treatment on the precision-distilled composition using chromatography.

Abstract: The present disclosure provides feed composition comprising at least one cyclopropenoid fatty acids or at least one conjugated linoleic acid and at least one cyclopropenoid fatty acids with normal or basal feed. After administration of one of the feed compositions, improved health aspects, reduced health issues, reduced mortality, increased carcass gain and repartitioning nutrients to muscles, and controlled carcass iodine value in non-human animals as compared to a control group not fed with the feed composition.

Abstract: A method for extracting naturally occurring oil bodies (oleosomes) from a material containing naturally occurring oil bodies (oleosomes) includes the steps of dispersing the material containing oleosomes in an aqueous composition to thereby obtain an aqueous dispersion of material containing oleosomes, extracting oleosomes from the aqueous dispersion of material containing oleosomes to thereby obtain a crude oleosome extract and isolating crude oleosomes from the extract by drying the crude oleosome extract. The dried oleosome powder may be used with a personal care product, a pharmaceutical product or a food product.

Abstract: Disclosed herein are conjugated polymers comprising a polymer and an all-trans retinoic acid (ATRA) prodrug covalently bound to the polymer by a hydrolysable linker L or a pharmaceutically acceptable salt thereof, and methods of using same to treat certain disorders. In an embodiment, the conjugated polymer comprises poly (vinyl alcohol) covalently bound to ATRA through an ester linkage.

Abstract: The present invention provides the use of a metformin salt, particularly metformin monothreonate, in the preparation of a medicament for treating cerebral infarction. The metaformin monothreonate of the present invention has an excellent effect in the treatment of cerebral infarction. The present invention also provides a method for preparing metformin monothreonate and a composition comprising metformin monothreonate.

Abstract: The present invention relates to a specialized pro-resolving lipid mediator comprising maresins, D-series resolvins, E-series resolvins, protectins or lipoxins, or a combination thereof, for use in the treatment of neurodegenerative diseases and/or autoimmune diseases.

Abstract: FSP27 compositions and methods for treating cancers are described.

Abstract: The invention concerns a nutritional or therapeutic agent comprising a molecule mix obtained from Vitis vinifera and Vaccinium angustifolium, comprising: at least 1% of catechins and epicatechins, the percentage being given by weight in relation to the total weight of the mix, preferably at least 5%, at least 5 ppm (parts per million in the mix) of ferulic acid, preferably at least 10 ppm. The invention also relates to the use of this agent due to its effects on cognitive functions in particular.

Abstract: A pharmaceutical combination comprising (A): a polyunsaturated fatty acid and (B): a chemotherapeutic agent compound for the simultaneous, separate or sequential use in the treatment of a cancer in a human patient.

Abstract: A nutraceutical formulation used to unblock receptors is disclosed herein. The nutraceutical formulation used to therapeutically treat humans includes arachidonic acid, docosahexaenoic acid (DHA), echinacea, kaempferol, coffee fruit, and probiotics.

Abstract: A method and system for flue gas reclamation is described. In one embodiment, a flue gas reclamation system is provided. The system includes a combustion engine including an intake member, an output shaft, and an exhaust outlet. The intake member receives flue gas from a gas source. A generator is connected to the output shaft and a compressor is connected to the exhaust outlet of the combustion engine. At least one holding tank is connected to the compressor and the compressor stores enriched flue gas from the exhaust outlet of the combustion engine in the at least one holding tank. A battery is connected to the generator and is configured to provide electric power to the flue gas reclamation system. An algae farm in fluid communication with the at least one holding tank is configured to receive the stored enriched flue gas from the at least one holding tank.

Abstract: Preservation of newly-extracted roe sacks of sturgeons for subsequent harvesting of roe and caviar production, wherein said preservation employs an oil derived from roe sack membrane normally discarded in conventional caviar production. Such preservation enables roe sacks with retained roe derived from farmed or wild sturgeon to be stored and transported whereby export can be considered. The same oil, or fatty acid-containing fractions thereof, may also find use in dietary compositions, e.g. pet foods.

Abstract: The present invention relates generally to methods for the treatment and/or prophylaxis of mental illness involving administration of 10-HDA. More particularly, methods are taught herein for the treatment and/or prophylaxis of obsessive compulsive disorder, anxiety disorder or a condition characterised by one or more symptoms of a obsessive compulsive disorder or an anxiety disorder.

Abstract: A synthetic nutritional composition comprising a fatty acid derivative for use to promote, support or optimise de novo myelination, in particular the de novo myelination trajectory, and/or brain structure, and/or brain connectivity, and/or intellectual potential and/or cognitive potential and/or learning potential and/or cognitive functioning in a subject, in particular a formula fed subject.

Abstract: The invention relates to methods of diagnosis, control and prophylaxis of inflammation and mitigation of inflammatory conditions, particularly arthritis and joint pain, in canines, comprising measuring inflammatory biomarkers wherein elevated levels of the biomarkers in blood correlates to reduced inflammation and reduced levels in blood correlates to increase level in the tissues. The invention further provides a method to treat or control inflammation comprising administering a diet comprising increased levels of one or more of DHA, EPA, vitamin C, vitamin E, and/or L-carnitine.

Abstract: Disclosed herein is the correlation of chemical properties of oils with the physical properties of a resulting cured oil composition. Also disclosed are biocompatible materials and coatings for medical devices prepared using enriched oils and methods for enhancing or modifying the physical and chemical characteristics of cured oils by enriching such oils with fatty acid alkyl esters. Methods of tailoring the properties of biocompatible materials and coatings to deliver one or more therapeutic agents are also provided.

Abstract: Compositions and methods for inducing immune tolerance to proteins and subsequence administration of the proteins are disclosed. Compositions comprise proteins complexed with liposomes comprising PS and PC, wherein at least part of the PS is present as lyso-PS.

Abstract: The present invention relates to compositions and methods comprising resveratrol and uses thereof. Some embodiments include compositions and methods with increased bioavailability of resveratrol. Certain embodiments include compositions comprising resveratrol and a solubilizer. Particular embodiments include transmucosal delivery of resveratrol from the composition.

Abstract: Therapeutic compounds useful for the treatment of pathogens including bacteria (gram positive and gram negative, mycobacteria), some fungi and viruses. The compounds described herein may include a mixture of therapeutically-effective amounts of a polar amino acid, a CI 1 fatty acid, and an anthraquinone. The invention further provides for the administration of the therapeutic compounds to a patient (e.g., a human) suffering from an infection.

Abstract: The present disclosure provides silylated polyalcohols, compositions thereof and their use as medical, insecticidal, prophylactic or therapeutic substances for the treatment or prevention of infection or infestation by arthropods. More specifically, the disclosure relates to the methods of treatment of infections or infestation by lice in a human comprising administration of an effective amount of silylated polyalcohols and compositions thereof.

Abstract: Mixtures of vitamin E and polyunsaturated fatty acids (PUFAs) are provided as agents for the prevention, control and/or treatment of conditions associated with excessive fat accumulation in the liver which is not caused by alcohol abuse, including control and/or treatment of non-alcoholic steatosis in the liver—known as non-alcoholic fatty liver disease (NAFLD)—and/or non-alcoholic steatohepatitis (NASH) in a subject in need thereof.

Abstract: The invention relates to the use of a very low dosage form of abscisic acid (ABA) or an in vivo hydrolysable conjugate thereof, preferably ABA-glucosyl ester (ABA-GE), for nutracentic/therapeutic use for controlling and/or preventing hyperglycaemia and weight gain in response to sugar intake with a reduction in insulin secret and an increase in muscle performance.

Abstract: Cosmetic composition for healing and treating the skin, the formula of which consists exclusively of compounds functional for the skin and/or compounds functional both for the skin and also for the structure of the formula.

Abstract: The invention provides a neck-worn sensor that is a single, body-worn system that measures the following parameters from an ambulatory patient: heart rate, pulse rate, pulse oximetry, respiratory rate, temperature, thoracic fluid levels, stroke volume, cardiac output, and a parameter sensitive to blood pressure called pulse transit time. From stroke volume, a first algorithm employing a linear model can estimate the patient's pulse pressure. And from pulse pressure and pulse transit time, a second algorithm, also employing a linear algorithm, can estimate systolic blood pressure and diastolic blood pressure. Thus, the sensor can measure all five vital signs along with hemodynamic parameters. It also includes a motion-detecting accelerometer, from which it can determine motion-related parameters such as posture, degree of motion, activity level, respiratory-induced heaving of the chest, and falls.

Abstract: The present invention relates generally to methods for the treatment and/or prophylaxis of neurological diseases and disorders involving administration of trans 10-HDA. In particular, the methods of the present invention are useful in the treatment and/or prophylaxis of acquired or progressive neurodevelopmental disorders and conditions in mammals. More particularly, methods are taught herein for the treatment and/or prophylaxis of diseases and disorders such as autism spectrum disorders.

Abstract: The present disclosure relates to synthesis of porous polymer networks and applications of such materials. The present disclosure relates to a method of fabricating of a porous polymer network comprising: (a) providing: (i) a first reactant comprising a plurality of compounds comprising at least one acetyl group, said plurality of compounds comprising at least one compound type, and (ii) a second reactant comprising an alkylsulfonic acid, and (b) creating a solution of said reactants, (c) casting said solution in a form, and (d) treating said solution under such conditions so as to produce a porous polymer network.

Abstract: A method for decreasing proliferation of cancer cells comprises the steps of administering a sensitizer. Sensitizers can include selenium, fish oil, and a combination of selenium and fish oil to a cancer cell. The method contemplates that the selenium and fish oil are administered in an amount effective to respectively increase the sensitivity of the cancer cells, and the administration of the combination of selenium and fish oil are administered in an amount effective to synergistically increase the sensitivity of the cancer cells more than the selenium or the fish oil alone. The method additionally exposes cancer cells to temperatures in excess of 37° C.

Abstract: A composition for the prophylaxis and/or treatment of a developmental disorder which is associated with preterm birth, and a method for the diagnosis and/or determination and/or prediction of the degree of severity of a developmental disorder which is associated with preterm birth.

Abstract: Described herein are compositions including at least one omega-3 fatty acid (either in the triglyceride, ester or free fatty acid ester form) and at least one surface active agent; wherein the compositions form micelles when in contact with an aqueous medium. Also provided are methods of administering to a subject a composition including at least one omega-3 fatty acid (either in the triglyceride, ester or free fatty acid ester form) and at least one surface active agent, wherein the compositions form micelles when in contact with an aqueous medium, and the bioavailability of the omega-3 fatty acid is substantially independent of a food effect.

Abstract: In various embodiments, the present invention provides methods of treating and/or preventing prostate cancer and, in particular, the method comprising administering to a subject in need thereof a pharmaceutical composition comprising eicosapentaenoic acid or a derivative thereof.

Abstract: Nitro oleic acid and related metabolites are agonists of PPAR-?. Surprisingly, nitro oleic acid is a more potent agonist of PPAR-?, relative to nitro linoleic acid. Thus, nitro oleic acid and its metabolites, as well as their pharmaceutically acceptable salts and prodrug forms, are candidate therapeutics for the treatment of type-2 diabetes, which results from insulin resistance accompanying the improper functioning of PPAR-?.

Abstract: Provided are: a composition containing 96-99 area % of eicosapentaenoic acid alkyl ester, the composition having an arachidonic acid alkyl ester content of 0.7 area % or less, and an eicosapentaenoic-acid-alkyl-ester mono-trans isomer content of 2.5 area % or less; and a method for producing a composition containing a high concentration of eicosapentaenoic acid alkyl ester, the method including performing precision distillation on a composition containing eicosapentaenoic acid alkyl ester, obtained by alkyl esterification of a raw material oil containing eicosapentaenoic acid, under a vacuum of 0.2 Torr or lower and a temperature of 190° C. or lower in the entire column, and performing a concentration treatment on the precision-distilled composition using chromatography.

Abstract: The present disclosure provides orally deliverable pharmaceutical compositions comprising DGLA and to methods of using same to treat a variety of conditions and disorders.

Abstract: The present invention relates to the compositions, formulations and methods of treating fatty liver disorders, such as non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) and their sequelae by administration of 15-OHEPA.

Abstract: An antibody-drug conjugate having a cyclic benzylidene acetal linker represented by formula (1) or formula (2), wherein Y is an antibody; D is a drug; R1 and R6 are each independently a hydrogen atom or a hydrocarbon group; R2, R3, R4 and R5 are each independently an electron-withdrawing or electron-donating substituent or a hydrogen atom; s is 1 or 2, t is 0 or 1, and s+t is 1 or 2; w is an integer of 1 to 20; and Z1 and Z2 are each independently a selected divalent spacer:

Abstract: Pharmaceutical combinations and methods for using such combinations to treat depression are disclosed. In various embodiments (the pharmaceutical combinations include combinations of omega-3 fatty acids, pharmacological sleep agents, and non-pharmacological sleep therapies, and may include other ingredients such as antidepressants. The present invention relates pharmaceutical combinations and methods for their use to treat depression.

Abstract: There is provided herein a method of treating a poikilothermic organism, such as marine bivalves, in a decreasing temperature environment which method comprises exposing the organism to a source of eicosapentaenoic acid (EPA) at temperatures of from 18° C. to about 12° C., and then exposing the organism to a source of docosahexaenoic acid (DHA) at temperatures of from about 11° C. to about 5° C. There is also provided herein a method of just conducting the first or second exposing step without the other, and also a method of using a decrease in temperature to catalyze the organism to produce EPA and/or DHA and/or non-methylene-interrupted fatty acids (NMIs).

Abstract: The present disclosure relates to compositions suitable as leave-in hairstyling compositions comprising (a) a first polysaccharide comprising inulin; (b) a second polysaccharide comprising carrageenan; (c) a third polysaccharide; and (d) a humectant. The compositions as leave-on hair styling do not require synthetic film-forming polymers nor do they require silicones. The leave-on hair styling compositions are particularly useful in methods for imparting durable styling or shaping benefits to hair.

Abstract: Disclosed herein are novel methodologies of treating fragile X syndrome and related disorders by inhibiting mGlu5-relevant signaling pathways via the reduction of ?-arrestin2 protein levels or the diminution of mGlu5 and ?-arrestin2 protein interactions.

Abstract: The invention provides compositions and methods for treatment of epilepsy in an animal. In one embodiment, a method for treating epilepsy in a companion animal can comprise administering to the companion animal a food composition comprising a medium chain triglyceride (MCT), wherein the MCT is present in the food composition in an effective amount for reducing or preventing seizures when the food composition is administered to the companion animal.

Abstract: The present invention relates to a polyunsaturated fatty acid composition comprising Omega-3 fatty acids, 17-HDHA and 18-HEPE. The composition can furthermore comprise DPA and/or an acceptable carrier and can be present in a capsule or other suitable dosage unit. The invention also relates to the process of obtaining the composition and methods for using same.

Abstract: This disclosure provides compounds, pharmaceutical compositions, and methods of use for the prevention and treatment of inflammatory diseases or degenerative diseases including neurodegenerative diseases. Embodiments of the present disclosure provide compounds related to very long chain polyunsaturated fatty acids, pharmaceutical compositions containing the provided compounds, and methods of treating a subject with a condition or disease using provided compounds or pharmaceutical compositions.

Abstract: Nitro oleic acid and related metabolites are agonists of PPAR-?. Surprisingly, nitro oleic acid is a more potent agonist of PPAR-?, relative to nitro linoleic acid. Thus, nitro oleic acid and its metabolites, as well as their pharmaceutically acceptable salts and prodrug forms, are candidate therapeutics for the treatment of type-2 diabetes, which results from insulin resistance accompanying the improper functioning of PPAR-?.

Abstract: Provided are: a composition containing 96-99 area % of eicosapentaenoic acid alkyl ester, the composition having an arachidonic acid alkyl ester content of 0.7 area % or less, and an eicosapentaenoic-acid-alkyl-ester mono-trans isomer content of 2.5 area % or less; and a method for producing a composition containing a high concentration of eicosapentaenoic acid alkyl ester, the method including performing precision distillation on a composition containing eicosapentaenoic acid alkyl ester, obtained by alkyl esterification of a raw material oil containing eicosapentaenoic acid, under a vacuum of 0.2 Torr or lower and a temperature of 190° C. or lower in the entire column, and performing a concentration treatment on the precision-distilled composition using chromatography.

Abstract: The present disclosure provides orally deliverable pharmaceutical compositions comprising DGLA and to methods of using same to treat a variety of conditions and disorders.